Health Alert:

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.

Penn Medicine Research at ASCO 2018 – What You Need to Know

At the American Society of Clinical Oncology (ASCO) Annual Meeting, more than 32,000 oncology professionals gather from around the world to discuss treatment modalities, new therapies and controversies in the field.

Penn Medicine and the Abramson Cancer Center will have a significant presence at the annual meeting of ASCO this year, which takes place June 1-5 in Chicago. CAR-T therapy, developed largely at Penn Medicine, is ASCO’s 2018 Clinical Cancer Advance of the Year.

The theme of the 2018 meeting, ‘Delivering Discoveries, Expanding the Reach of Precision Medicine’, is a familiar theme at Abramson Cancer Center — representative of Penn’s ongoing efforts to bring tangible advances in therapy to patients throughout the cancer spectrum.

Featured Penn Researchers at ASCO 2018 

Dr. Susan M. Domchek of the Basser Center for BRCA at Penn MedicineSusan Domchek, MD ─ Dr. Domchek will be among the expert faculty discussing the use of PARP inhibitor therapy in breast cancer therapy on June 1. Executive Director of the Basser Center for BRCA at Penn Medicine, Dr. Domchek will join thought leaders from Sloan Kettering, Stanford and UCLA to consider the efficacy of the PARP inhibitors and strategies to identify and mitigate predictable treatment-related adverse events.

Dr. Marcia Brose

 Marcia Brose, MD, PhD On June 2, Dr. Brose will be presenting data from a phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting, for which she was lead author and principal investigator. Dr. Brose led the phase III DECISION clinical trial at Penn Medicine for sorafenib, the first kinase inhibitor to receive FDA approval for the treatment of RAI-refractory DTC.

CAR-T: ASCO’s 2018 Clinical Advance of the Year 

CAR-T therapy, named ASCO’s 2018 clinical Advance of the Year, will be represented at the ASCO meeting by Penn Medicine physician researchers, Drs. Carl June and Adam D. Cohen. 

carl june thumbnail

Kymriah recently received a second indication for diffuse large B cell lymphoma, the most common form of non-Hodgkin lymphoma. A pioneer of CAR-T therapy, Carl June, MD, will be presenting on genetically modified cell therapy on June 4. Dr. June was a principal investigator at Penn Medicine for the clinical trials that led to the FDA approval of Kymriah™ (tisagenlecleucel) for the treatment of refractory acute lymphocytic leukemia (ALL) in children and young adults.

Dr. Adam CohenAdam D. Cohen, MD, will be reviewing CAR-T and Cellular Therapy in Myeloma on June 1 at a session devoted to precision medicine in myeloma. In addition to the topic heading, the session will review risk stratification and current indications for the use of immunotherapy in patients with high-risk multiple myeloma, based on recent evidence.

For ongoing updates from ASCO 2018, follow #ASCO18@PennMedNews and @PennMDForum on Twitter.

 

About this Blog

The Penn Physician Blog is a resource for health care professionals featuring Penn Medicine physicians and their research, innovations, programs and events. 

Date Archives

GO
Share This Page: